Loading...

SONM DNA X INC Management Changes 8-K Filing

DN X

SNM

DNA X INC

(SONM)

2026 8-K

Funding Agreement

Financial Results Announced

Accountant Change

Financial Results Announced

Acquisition Reporting

CEO Appointment

Management Changes

Asset Sale Completion

Asset Sale Approved

Corporate Investment Update

Retention Bonus Approved

Asset Purchase Update

Nasdaq Compliance Regained

Financial Results Announced

Stock Split Approved

Equity Facility Agreement

Nasdaq Listing Deficiency

Delisting Notice

Compensatory Arrangements o...

Asset Acquisitions

Debt Restructuring

Equity Offerings

Merger of Equals

Equity Offerings

Financial Statements

Stockholder Rights Agreement

CFO Agreement Update

CEO Agreement Update

Financial Results

Note Purchase Agreement

Employee Incentives

Strategic Review

Financial Results

Financial Results

Receivables Financing

Earnings Reports

Sales Agreement

Compliance with Nasdaq List...

Reverse Stock Split

Reverse Stock Split

Annual Meeting Approval

Amendments to Bylaws

Amendment to Registration R...

Amendment to 2024 Annual Me...

Earnings Reports

Private Placement

Financial Results Announcement

Employment Agreements

Financial Results Announcement

Earnings Release

Retirement of Directors

Correction of Press Release

Financial Results Announcement

SEC Investigation Conclusion

External Links:

On February 9, 2026, DNA X, Inc. appointed Mike Mulica as acting CEO with a new annual salary of $450,000 and 50,000 restricted stock units; also amended CFO Clay Crolius's agreement with 35,000 RSUs following an asset sale on January 23, 2026.

AI Assistant

DNA X INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.